Skip to main content

A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck

Start Date

March 24, 2017

End Date

June 30, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Merck

Start Date

March 24, 2017

End Date

June 30, 2022